These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 30496013)

  • 1. Reply to F. Liang.
    Pietanza MC; Diao L; Wang J; Byers LA
    J Clin Oncol; 2019 Jan; 37(3):259. PubMed ID: 30496013
    [No Abstract]   [Full Text] [Related]  

  • 2. SLFN11: a new synthetic lethal target?
    Sidaway P
    Nat Rev Clin Oncol; 2018 Sep; 15(9):533. PubMed ID: 29959392
    [No Abstract]   [Full Text] [Related]  

  • 3. Is SLFN11 a Promising Predictive Biomarker of Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Small-Cell Lung Cancer? Not Yet!
    Liang F
    J Clin Oncol; 2019 Jan; 37(3):259. PubMed ID: 30496012
    [No Abstract]   [Full Text] [Related]  

  • 4. New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy.
    Rosière R; Gelbcke M; Mathieu V; Van Antwerpen P; Amighi K; Wauthoz N
    Int J Oncol; 2015 Sep; 47(3):1131-42. PubMed ID: 26201404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Veliparib plus temozolomide in metastatic melanoma trends toward increased PFS but results are not statistically significant.
    Oncology (Williston Park); 2011 Nov; 25(12):1213, 1232. PubMed ID: 22229218
    [No Abstract]   [Full Text] [Related]  

  • 6. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
    Liu X; Shi Y; Guan R; Donawho C; Luo Y; Palma J; Zhu GD; Johnson EF; Rodriguez LE; Ghoreishi-Haack N; Jarvis K; Hradil VP; Colon-Lopez M; Cox BF; Klinghofer V; Penning T; Rosenberg SH; Frost D; Giranda VL; Luo Y
    Mol Cancer Res; 2008 Oct; 6(10):1621-9. PubMed ID: 18922977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer.
    Ebert BL; Niemierko E; Shaffer K; Salgia R
    Oncologist; 2003; 8(1):69-75. PubMed ID: 12604733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
    Chua D; Krzakowski M; Chouaid C; Pallotta MG; Martinez JI; Gottfried M; Curran W; Throuvalas N
    Clin Lung Cancer; 2010 May; 11(3):176-81. PubMed ID: 20439193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.
    Nuthalapati S; Munasinghe W; Giranda V; Xiong H
    Clin Pharmacokinet; 2018 Jan; 57(1):51-58. PubMed ID: 28497258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965).
    Dziadziuszko R; Ardizzoni A; Postmus PE; Smit EF; Price A; Debruyne C; Legrand C; Giaccone G;
    Eur J Cancer; 2003 Jun; 39(9):1271-6. PubMed ID: 12763216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of temozolomide against human tumor colony-forming units.
    Raymond E; Izbicka E; Soda H; Gerson SL; Dugan M; Von Hoff DD
    Clin Cancer Res; 1997 Oct; 3(10):1769-74. PubMed ID: 9815562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
    Abrey LE; Olson JD; Raizer JJ; Mack M; Rodavitch A; Boutros DY; Malkin MG
    J Neurooncol; 2001 Jul; 53(3):259-65. PubMed ID: 11718258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide-Perillyl alcohol conjugate impairs Mitophagy flux by inducing lysosomal dysfunction in non-small cell lung Cancer cells and sensitizes them to irradiation.
    Chang M; Song X; Geng X; Wang X; Wang W; Chen TC; Xie L; Song X
    J Exp Clin Cancer Res; 2018 Oct; 37(1):250. PubMed ID: 30326943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity.
    Muldoon LL; Pagel MA; Netto JP; Neuwelt EA
    J Neurooncol; 2016 Feb; 126(3):447-54. PubMed ID: 26694547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
    Pacheco JM; Byers LA
    Cancer Discov; 2019 Oct; 9(10):1340-1342. PubMed ID: 31575562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
    Paul MJ; Summers Y; Calvert AH; Rustin G; Brampton MH; Thatcher N; Middleton MR
    Melanoma Res; 2002 Apr; 12(2):175-8. PubMed ID: 11930115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Domperidone stimulating antral and duodenal motility in a double-blind crossover study].
    Weihrauch TR; Ehl W; Ewe K; Förster CF
    Verh Dtsch Ges Inn Med; 1978; (84):994-7. PubMed ID: 369215
    [No Abstract]   [Full Text] [Related]  

  • 19. Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study.
    Kouroussis C; Vamvakas L; Vardakis N; Kotsakis A; Kalykaki A; Kalbakis K; Saridaki Z; Kentepozidis N; Giassas S; Georgoulias V
    Oncology; 2009; 76(2):112-7. PubMed ID: 19142045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide-perillyl alcohol conjugate downregulates O
    Song X; Xie L; Chang M; Geng X; Wang X; Chen TC; Song X
    Cell Death Dis; 2018 Feb; 9(2):202. PubMed ID: 29426908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.